{"id":79089,"date":"2022-07-25T23:28:58","date_gmt":"2022-07-25T21:28:58","guid":{"rendered":"https:\/\/www.csregypt.com\/?p=79089"},"modified":"2022-07-25T23:31:28","modified_gmt":"2022-07-25T21:31:28","slug":"moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants","status":"publish","type":"post","link":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/","title":{"rendered":"Moderna first global company to introduce bivalent vaccine against Omicron variants"},"content":{"rendered":"

Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, is the first global company to introduce a bivalent vaccine<\/a> for protection against Omicron variants.<\/p>\n

Moderna announced new clinical data on its Omicron containing bivalent COVID booster candidate, mRNA-1273.214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern.<\/p>\n

A 50 \u03bcg booster dose of mRNA-1273.214 met all pre-specified endpoints including superior neutralizing antibody response (geometric mean ratio) against the Omicron variant,<\/p>\n

One month after administration when compared to the original mRNA-1273 vaccine. The booster dose of mRNA-1273.214 was generally well tolerated, with side effects comparable to a booster dose of mRNA-1273 at the 50 \u03bcg dose level.<\/p>\n

\u00a0“We are thrilled to share the preliminary data analysis on mRNA-1273.214, which is the second demonstration of superiority of our bivalent booster platform against variants of concern and represents an innovation in the fight against COVID,” said St\u00e9phane Bancel, Chief Executive officer of Moderna.<\/p>\n

“Looking at these data alongside the durability we saw with our _first bivalent booster candidate, mRNA-1273.211, we anticipate more durable protection against variants of concern with mRNA-1273.214, making it our lead candidate for a Fall 2022 booster. We are submitting our preliminary data and analysis to regulators with the hope that the Omicron-containing bivalent booster will be available in the late summer. Taken together, our bivalent booster candidates demonstrate the power of Moderna’s mRNA platform to develop vaccines that meet immediate, global public health threats.”<\/p>\n

\"\"<\/p>\n

\u00a0Dr. Nibal Dahaba, Managing director & cofounder of Gennecs Holding & Gennvax Moderna’s legal exclusive representative in Egypt, expressed her pride in the new bivalent vaccine’s remarkable achievements, and affirmed that the findings will result in massive protection against the virus and its mutations.<\/p>\n

A booster dose of mRNA-1273.214 increased neutralizing geometric mean titers (GMT) against Omicron approximately 8-fold above baseline levels. Primary endpoints of non-inferiority against ancestral SARS-CoV-2 were also met, with GMR against ancestral SAR-COV-2 (D614G) of 1.22 (1.08-1.37).<\/p>\n

Binding antibody titers (MSD) were also significantly higher (nominal alpha of 0.05) against all other variants of concern (Alpha, Beta, Gamma, Delta, Omicron) for mRNA-1273.214 when compared to mRNA-1273.<\/p>\n

\u00a0The mRNA-1273.214 50 \u03bcg booster dose was well-tolerated in the 437 study participants. The safety and reactogenicity profile of the mRNA-1273.214 50\u03bc g booster dose was similar to that of mRNA-1273 50\u03bc g dose when these vaccines were administered as a second booster dose.<\/p>\n

\u00a0In February 2021, Moderna announced its strategy to update booster candidates to address the ongoing evolution of the SARS-CoV-2 virus, including monovalent and bivalent candidates targeting multiple variants of concern. The Company’s primary focus has been on the bivalent booster approach, which are boosters that address two viral strains simultaneously.<\/p>\n

\u00a0Results from the Company’s Beta-containing bivalent booster candidate, mRNA-1273.211 announced in April 2022, demonstrated superiority against Beta, Delta and Omicron variants of concern one month after administration, with continued superiority that was durable against Beta and Omicron variants of concern six months after administration. Given the significantly higher antibody titers induced by mRNA-1273.214 compared to mRNA-1273,<\/p>\n

Moderna anticipates that antibody titers induced by mRNA-1273.214 will be more durable over time against Omicron as compared to mRNA-1273. Moderna will report data from Day 91 after vaccination later in the summer.<\/p>\n","protected":false},"excerpt":{"rendered":"

Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, is the first global company to introduce a bivalent vaccine for protection against Omicron variants. Moderna announced new clinical data on its Omicron containing bivalent COVID booster candidate, mRNA-1273.214, containing mRNA-1273 (Spikevax) and a vaccine candidate targeting the Omicron variant of concern. A 50 […]<\/p>\n","protected":false},"author":410,"featured_media":79092,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6031,984],"tags":[],"yoast_head":"\nModerna first global company to introduce bivalent vaccine against Omicron variants - Csr Egypt<\/title>\n<meta name=\"description\" content=\"Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, is the first global company to introduce a bivalent vaccine for protection against Omicron variants.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moderna first global company to introduce bivalent vaccine against Omicron variants - Csr Egypt\" \/>\n<meta property=\"og:description\" content=\"Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, is the first global company to introduce a bivalent vaccine for protection against Omicron variants.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/\" \/>\n<meta property=\"og:site_name\" content=\"Csr Egypt\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/csregypt\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-25T21:28:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-25T21:31:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/07\/a91eaaeb-d5ec-40bb-9ba8-a13b97f5c526.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"527\" \/>\n\t<meta property=\"og:image:height\" content=\"582\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Marwa Zein\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@egyptcsrforum\" \/>\n<meta name=\"twitter:site\" content=\"@egyptcsrforum\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marwa Zein\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/\"},\"author\":{\"name\":\"Marwa Zein\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec\"},\"headline\":\"Moderna first global company to introduce bivalent vaccine against Omicron variants\",\"datePublished\":\"2022-07-25T21:28:58+00:00\",\"dateModified\":\"2022-07-25T21:31:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/\"},\"wordCount\":540,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/csregypt.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/07\/a91eaaeb-d5ec-40bb-9ba8-a13b97f5c526.jpg\",\"articleSection\":[\"health\",\"news\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/\",\"url\":\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/\",\"name\":\"Moderna first global company to introduce bivalent vaccine against Omicron variants - Csr Egypt\",\"isPartOf\":{\"@id\":\"https:\/\/csregypt.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/07\/a91eaaeb-d5ec-40bb-9ba8-a13b97f5c526.jpg\",\"datePublished\":\"2022-07-25T21:28:58+00:00\",\"dateModified\":\"2022-07-25T21:31:28+00:00\",\"description\":\"Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, is the first global company to introduce a bivalent vaccine for protection against Omicron variants.\",\"breadcrumb\":{\"@id\":\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#primaryimage\",\"url\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/07\/a91eaaeb-d5ec-40bb-9ba8-a13b97f5c526.jpg\",\"contentUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/07\/a91eaaeb-d5ec-40bb-9ba8-a13b97f5c526.jpg\",\"width\":527,\"height\":582,\"caption\":\"Moderna first global company to introduce bivalent vaccine for protection against Omicron variants\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/csregypt.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moderna first global company to introduce bivalent vaccine against Omicron variants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/csregypt.com\/#website\",\"url\":\"https:\/\/csregypt.com\/\",\"name\":\"\u0633\u064a \u0625\u0633 \u0622\u0631 \u0645\u0635\u0631\",\"description\":\"The first portal for CSR in Egypt and Middle East\",\"publisher\":{\"@id\":\"https:\/\/csregypt.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/csregypt.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/csregypt.com\/#organization\",\"name\":\"CSR\",\"url\":\"https:\/\/csregypt.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png\",\"contentUrl\":\"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png\",\"width\":1080,\"height\":1080,\"caption\":\"CSR\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/csregypt\/\",\"https:\/\/x.com\/egyptcsrforum\",\"https:\/\/www.instagram.com\/csr.egypt\/\",\"https:\/\/www.linkedin.com\/in\/csr-egypt-43381ab5\/\",\"https:\/\/www.pinterest.com.au\/csregypt\/\",\"https:\/\/www.youtube.com\/channel\/UCh21PZpnBj2yjj2PeclXz1g\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec\",\"name\":\"Marwa Zein\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g\",\"caption\":\"Marwa Zein\"},\"sameAs\":[\"http:\/\/marwazein1982@gmail.com\"],\"url\":\"https:\/\/csregypt.com\/en\/author\/marwa-zein\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moderna first global company to introduce bivalent vaccine against Omicron variants - Csr Egypt","description":"Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, is the first global company to introduce a bivalent vaccine for protection against Omicron variants.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/","og_locale":"en_US","og_type":"article","og_title":"Moderna first global company to introduce bivalent vaccine against Omicron variants - Csr Egypt","og_description":"Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, is the first global company to introduce a bivalent vaccine for protection against Omicron variants.","og_url":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/","og_site_name":"Csr Egypt","article_publisher":"https:\/\/www.facebook.com\/csregypt\/","article_published_time":"2022-07-25T21:28:58+00:00","article_modified_time":"2022-07-25T21:31:28+00:00","og_image":[{"width":527,"height":582,"url":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/07\/a91eaaeb-d5ec-40bb-9ba8-a13b97f5c526.jpg","type":"image\/jpeg"}],"author":"Marwa Zein","twitter_card":"summary_large_image","twitter_creator":"@egyptcsrforum","twitter_site":"@egyptcsrforum","twitter_misc":{"Written by":"Marwa Zein","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#article","isPartOf":{"@id":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/"},"author":{"name":"Marwa Zein","@id":"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec"},"headline":"Moderna first global company to introduce bivalent vaccine against Omicron variants","datePublished":"2022-07-25T21:28:58+00:00","dateModified":"2022-07-25T21:31:28+00:00","mainEntityOfPage":{"@id":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/"},"wordCount":540,"commentCount":0,"publisher":{"@id":"https:\/\/csregypt.com\/#organization"},"image":{"@id":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#primaryimage"},"thumbnailUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/07\/a91eaaeb-d5ec-40bb-9ba8-a13b97f5c526.jpg","articleSection":["health","news"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/","url":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/","name":"Moderna first global company to introduce bivalent vaccine against Omicron variants - Csr Egypt","isPartOf":{"@id":"https:\/\/csregypt.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#primaryimage"},"image":{"@id":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#primaryimage"},"thumbnailUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/07\/a91eaaeb-d5ec-40bb-9ba8-a13b97f5c526.jpg","datePublished":"2022-07-25T21:28:58+00:00","dateModified":"2022-07-25T21:31:28+00:00","description":"Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, is the first global company to introduce a bivalent vaccine for protection against Omicron variants.","breadcrumb":{"@id":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#primaryimage","url":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/07\/a91eaaeb-d5ec-40bb-9ba8-a13b97f5c526.jpg","contentUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/07\/a91eaaeb-d5ec-40bb-9ba8-a13b97f5c526.jpg","width":527,"height":582,"caption":"Moderna first global company to introduce bivalent vaccine for protection against Omicron variants"},{"@type":"BreadcrumbList","@id":"https:\/\/csregypt.com\/en\/moderna-first-global-company-to-introduce-bivalent-vaccine-against-omicron-variants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/csregypt.com\/"},{"@type":"ListItem","position":2,"name":"Moderna first global company to introduce bivalent vaccine against Omicron variants"}]},{"@type":"WebSite","@id":"https:\/\/csregypt.com\/#website","url":"https:\/\/csregypt.com\/","name":"\u0633\u064a \u0625\u0633 \u0622\u0631 \u0645\u0635\u0631","description":"The first portal for CSR in Egypt and Middle East","publisher":{"@id":"https:\/\/csregypt.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/csregypt.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/csregypt.com\/#organization","name":"CSR","url":"https:\/\/csregypt.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png","contentUrl":"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png","width":1080,"height":1080,"caption":"CSR"},"image":{"@id":"https:\/\/csregypt.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/csregypt\/","https:\/\/x.com\/egyptcsrforum","https:\/\/www.instagram.com\/csr.egypt\/","https:\/\/www.linkedin.com\/in\/csr-egypt-43381ab5\/","https:\/\/www.pinterest.com.au\/csregypt\/","https:\/\/www.youtube.com\/channel\/UCh21PZpnBj2yjj2PeclXz1g"]},{"@type":"Person","@id":"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec","name":"Marwa Zein","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g","caption":"Marwa Zein"},"sameAs":["http:\/\/marwazein1982@gmail.com"],"url":"https:\/\/csregypt.com\/en\/author\/marwa-zein\/"}]}},"jetpack_featured_media_url":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/07\/a91eaaeb-d5ec-40bb-9ba8-a13b97f5c526.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/79089"}],"collection":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/users\/410"}],"replies":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/comments?post=79089"}],"version-history":[{"count":3,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/79089\/revisions"}],"predecessor-version":[{"id":79096,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/79089\/revisions\/79096"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/media\/79092"}],"wp:attachment":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/media?parent=79089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/categories?post=79089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/tags?post=79089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}